This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Arecor Proprietary Pipeline
Using our Arestat™ technology platform, we are developing enhanced medicines for the treatment of diabetes and other chronic conditions
Tetris Pharma Portfolio
Our specialty pharmaceutical experts in registering, marketing, sales and the distribution of commercial-stage speciality hospital products across the UK and Europe
Our Partners
We partner with leading pharmaceutical and biotechnology companies through technology partnerships to enhance their proprietary products across a range of indications and stages of development
Latest News and Events
-
21st May 2024
ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES
-
20th May 2024
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES
-
9th May 2024
ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY